Nymox Pharmaceutical Corporation (NYMXF)
OTCMKTS
· Delayed Price · Currency is USD
0.0960
-0.0040 (-4.00%)
Jul 3, 2025, 10:50 AM EDT
Nymox Pharmaceutical Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Cash & Equivalents | 0.07 | 0.07 | 1.4 | 0.83 | 3.61 | Upgrade
|
Cash & Short-Term Investments | 0.07 | 0.07 | 1.4 | 0.83 | 3.61 | Upgrade
|
Cash Growth | 5.71% | -95.01% | 69.04% | -77.02% | -31.08% | Upgrade
|
Other Receivables | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade
|
Receivables | 0.03 | 0.01 | 0.01 | 0.01 | 0.02 | Upgrade
|
Inventory | - | - | - | 0.03 | 0.03 | Upgrade
|
Prepaid Expenses | 0.02 | 0.02 | 0.02 | 0.13 | 0.2 | Upgrade
|
Other Current Assets | 0.54 | 0.53 | 0.03 | 0.03 | 0.03 | Upgrade
|
Total Current Assets | 0.65 | 0.63 | 1.46 | 1.04 | 3.89 | Upgrade
|
Property, Plant & Equipment | 0 | 0 | 0.17 | 0.41 | 0.45 | Upgrade
|
Total Assets | 0.65 | 0.63 | 1.63 | 1.44 | 4.34 | Upgrade
|
Accounts Payable | 4.12 | 3.02 | 1.7 | 1.27 | 1.4 | Upgrade
|
Accrued Expenses | 0.03 | 0.03 | 0.24 | 0.29 | 0.32 | Upgrade
|
Short-Term Debt | 3.29 | 0.75 | - | - | - | Upgrade
|
Current Portion of Leases | - | - | 0.17 | 0.23 | 0.19 | Upgrade
|
Other Current Liabilities | - | - | - | - | 0.05 | Upgrade
|
Total Current Liabilities | 7.43 | 3.8 | 2.11 | 1.79 | 1.97 | Upgrade
|
Long-Term Leases | - | - | - | 0.16 | 0.23 | Upgrade
|
Total Liabilities | 7.43 | 3.8 | 2.11 | 1.95 | 2.2 | Upgrade
|
Common Stock | 173.88 | 173.82 | 171.67 | 165.06 | 151.72 | Upgrade
|
Additional Paid-In Capital | 28.01 | 27.78 | 26.99 | 27.58 | 31.04 | Upgrade
|
Retained Earnings | -212.47 | -207.98 | -199.14 | -192.56 | -180.03 | Upgrade
|
Comprehensive Income & Other | 3.81 | 3.21 | - | -0.59 | -0.59 | Upgrade
|
Total Common Equity | -6.78 | -3.17 | -0.48 | -0.51 | 2.15 | Upgrade
|
Shareholders' Equity | -6.78 | -3.17 | -0.48 | -0.51 | 2.15 | Upgrade
|
Total Liabilities & Equity | 0.65 | 0.63 | 1.63 | 1.44 | 4.34 | Upgrade
|
Total Debt | 3.29 | 0.75 | 0.17 | 0.39 | 0.43 | Upgrade
|
Net Cash (Debt) | -3.21 | -0.68 | 1.23 | 0.44 | 3.19 | Upgrade
|
Net Cash Growth | - | - | 180.18% | -86.22% | -37.45% | Upgrade
|
Net Cash Per Share | -0.03 | -0.01 | 0.01 | 0.01 | 0.04 | Upgrade
|
Filing Date Shares Outstanding | 94.54 | 93.54 | 91.27 | 90.28 | 78.71 | Upgrade
|
Total Common Shares Outstanding | 94.54 | 93.54 | 90.52 | 85.55 | 77.96 | Upgrade
|
Working Capital | -6.78 | -3.18 | -0.65 | -0.75 | 1.93 | Upgrade
|
Book Value Per Share | -0.07 | -0.03 | -0.01 | -0.01 | 0.03 | Upgrade
|
Tangible Book Value | -6.78 | -3.17 | -0.48 | -0.51 | 2.15 | Upgrade
|
Tangible Book Value Per Share | -0.07 | -0.03 | -0.01 | -0.01 | 0.03 | Upgrade
|
Machinery | 0.6 | 0.6 | 0.59 | 0.59 | 0.59 | Upgrade
|
Updated Jan 2, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.